Traders Are Watching: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), PriceSmart Inc. (NASDAQ:PSMT), Prospect Capital Corporation (NASDAQ:PSEC), RadiSys Corporation (NASDAQ:RSYS), INSYS Therapeutics, Inc. (NASDAQ:INSY)

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares advanced 2.33% in last trading session and ended the day at $7.46. PGNX Gross Margin is 99.10% and its return on assets is -17.10%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) quarterly performance is 24.96%. On July 7, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced details of its planned Phase 3 clinical trial for 1404, a developmental stage small molecule designed to help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA). Following recent End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), the design and key elements of a Phase 3 clinical trial for 1404 have been finalized.

On 10 July, PriceSmart Inc. (NASDAQ:PSMT) shares advanced 3.94% and was closed at $95.47. PSMT EPS growth in last 5 year was 16.50%. PriceSmart Inc. (NASDAQ:PSMT) year to date (YTD) performance is 5.10%. PriceSmart, Inc. (NASDAQ:PSMT) announced its results of operations for the third quarter of fiscal year 2015 which ended on May 31, 2015.For the third quarter of fiscal year 2015, net warehouse club sales increased 13.0% to $675.3 million from $597.9 million in the third quarter of fiscal year 2014.

Prospect Capital Corporation (NASDAQ:PSEC) ended the last trading day at $7.37. Company weekly volatility is calculated as 1.40% and price to cash ratio as 41.58. Prospect Capital Corporation (NASDAQ:PSEC) showed a weekly performance of -0.67%. Prospect Capital Corporation (NASDAQ:PSEC announced that Grier Eliasek, President and Chief Operating Officer, presented live at on July 9, 2015.

RadiSys Corporation (NASDAQ:RSYS) shares advanced 1.57% in last trading session and ended the day at $2.58. RSYS Gross Margin is 26.90% and its return on assets is -15.30%. RadiSys Corporation (NASDAQ:RSYS) quarterly performance is 23.44%. On July 08, Radisys Corporation (NASDAQ: RSYS), announced the appointment of Ron de Lange to its Board of Directors. Mr. de Lange most recently served as President and CEO of Tekelec, a leading global networking software company focused on enabling people and devices globally to talk, text, and access the internet. During his tenure at Tekelec, Ron successfully led the sale of Tekelec to Siris Capital and ultimately the strategic acquisition by Oracle in March 2013. Prior to becoming President and CEO of Tekelec, he served as Executive Vice President of Tekelec’s Global Product Solutions group and held a variety of key management positions at Lucent Technologies.

INSYS Therapeutics, Inc. (NASDAQ:INSY) belongs to Healthcare sector. Its net profit margin is 15.20% and weekly performance is 5.72%. On last trading day company shares ended up $37.53. INSYS Therapeutics, Inc. (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is 15.75%.

Leave a Reply

Your email address will not be published. Required fields are marked *